×

Klietz, Dr. med. Martin

Veröffentlichungen

Originalpublikationen

  • Depboylu C, Schorlemmer K, Klietz M, Oertel WH, Weihe E, Höglinger GU, Schäfer
    MK (2011) Upregulation of microglial C1q expression has no effects on nigrostriatal
    dopaminergic injury in the MPTP mouse model of Parkinson disease. J.
    Neuroimmunol. 236:39-46.
  • Matusch A, Fenn LS, Depboylu C, Klietz M, Strohmer S, McLean JA, Becker JS
    (2012) Combined elemental and biomolecular mass spectrometry imaging for probing
    the inventory of tissue at a micrometer scale. Anal. Chem. 84: 3170-3178.
  • Sussulini A, Matusch A, Klietz M, Bauer A, Depboylu C, Becker JS (2012)
    Quantitative imaging of Cu, Fe, Mn and Zn in the L-DOPA-treated unilateral 6-
    hydroxydopamine Parkinson’s disease mouse model by LA-ICP-MS. Biomedical
    Spectroscopy and Imaging 1: 125-136.
  • Schäfer MK, Hartwig NR, Kalmbach N, Klietz M, Anlauf M, Eiden LE, Weihe E
    (2013) Species-specific vesicular monoamine transporter 2 (VMAT2) expression
    inmammalian pancreatic beta cells: implications for optimising radioligand-based
    human beta cell mass (BCM) imaging in animal models. Diabetologia 56:1047-1056.
  • Depboylu C, Klietz M, Maurer L, Oertel WH, Kobayashi K, Weihe E, Höglinger GU,
    Schäfer MK (2014) Transcriptional and structural plasticity of tyrosine hydroxylase
    expressing neurons in both striatum and nucleus accumbens following dopaminergic
    denervation. J. Chem. Neuroanatomy 61-62:169-175.
  • Keber U, Klietz M, Carlsson T, Oertel WH, Weihe E, Schäfer MK, Höglinger GU,
    Depboylu C (2015) Striatal tyrosine hydroxylase-positive neurons are associated with
    L-DOPA induced dyskinesia in hemiparkinsonian mice. Neuroscience 298:302-17.
  • Klietz M, Keber U, Carlsson T, Chiu W-H, Höglinger GU, Weihe E, Schäfer M K-H,
    Depboylu C (2016) L-DOPA-induced dyskinesia is associated with a deficient
    numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
    Neuroscience 331:120-133.
  • Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, Wegner F.
    (2018) Impaired Quality of Life and Need for Palliative Care in a German Cohort of
    Advanced Parkinson’s Disease Patients. Front Neurol. 2018 Mar 6;9:120. doi:
    10.3389/fneur.2018.00120.
  • Stanslowsky N, Tharmarasa S, Staege S, Kalmbach N, Klietz M, Schwarz SC, Leffler
    A, Wegner F. Calcium, Sodium, and Transient Receptor Potential Channel Expression
    in Human Fetal Midbrain-Derived Neural Progenitor Cells. Stem Cells Dev. 2018 Jul
    15;27(14):976-984.
  • Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F (2019).
    Validating the Parkinson’s disease caregiver burden questionnaire (PDCB) in German
    caregiver of advanced Parkinson’s disease patients. International Psychogeriatrics.
    2019 Mar 25:1-10. doi: 10.1017/S1041610219000206.
  • Klietz M, Greten S, Wegner F, Höglinger GU (2019). Safety and Tolerability of
    Pharmacotherapies for Parkinson’s Disease in Geriatric Patients. Drugs and Aging.
    2019 Apr 2. doi: 10.1007/s40266-019-00654-z.
  • Paracka L, Kollewe K, Klietz M, Petri S, Dressler D. IncobotulinumtoxinA for
    hypersalivation in patients with amyotrophic lateral sclerosis: an open-label singlecentre study. J Neural Transm (Vienna). 2019 Oct;126(10):1341–5.
  • Klietz M, Bronzlik P, Nösel P, Wegner F, Dressler DW, Dadak M, Maudsley AA,
    Sheriff S, Lanfermann H, Ding X. Altered Neurometabolic Profile in Early Parkinson’s
    Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging.
    Front Neurol. 2019 Jul 17;10:406–11.
  • Klietz M, Öcalan Ö, Schneider N, Dressler D, Stiel S, Wegner F. Advance Directives
    of German People with Parkinson’s Disease Are Unspecific in regard to Typical
    Complications. Parkinson’s Disease. Hindawi; 2019 Aug 4;2019:1–8.
  • Drexel SC, Klietz M, Kollewe K, Paracka L, Kutschenko A, Kopp B, Lange F, Wegner
    F, Dressler D. Caregiver burden and health-related quality of life in idiopathic dystonia
    patients under botulinum toxin treatment: a cross-sectional study. J Neural Transm.
    Springer Vienna; 2020 Jan;127(1):61–70.
  • Piot I, Schweyer K, Respondek G, Stamelou M, ProPSP Study Group, Sckopke P,
    Schenk T, Goetz CG, Stebbins GT, Höglinger GU. The Progressive Supranuclear Palsy
    Clinical Deficits Scale. Mov Disord. 2020 Apr;35(4):650–61.
  • Klietz M, Drexel SC, Schnur T, Lange F, Groh A, Paracka L, Greten S, Dressler D,
    Höglinger GU, Wegner F. Mindfulness and Psychological Flexibility are Inversely
    Associated with Caregiver Burden in Parkinson’s Disease. Brain Sciences.
    Multidisciplinary Digital Publishing Institute; 2020 Feb;10(2):111–10.
  • Klietz M, Berndt JM, Wegner F, Schneider N, Höglinger GU, Eggers C, Stiel S.
    Consensus-Based Recommendations for Advance Directives of People with
    Parkinson’s Disease in Regard to Typical Complications by German Movement
    Disorder Specialists. JCM. Multidisciplinary Digital Publishing Institute; 2020
    Feb;9(2):449–14.
  • Klietz M, Schnur T, Drexel S, Lange F, Tulke A, Rippena L, Paracka L, Dressler D,
    Höglinger GU, Wegner F. Association of Motor and Cognitive Symptoms with Health-
    Related Quality of Life and Caregiver Burden in a German Cohort of Advanced
    Parkinson’s Disease Patients. Parkinson’s Disease. Hindawi; 2020 Feb 24;2020:1–8.
  • Kutschenko A, Klietz M, Paracka L, Kollewe K, Schulte-Sutum A, Janssen T, Schrader
    C, Wegner F, Dressler D. Dysphagia in cervical dystonia patients receiving optimised
    botulinum toxin therapy: a single-center retrospective cohort study. J Neural Transm
    (Vienna). 2020;127(8):1161-1165.
  • Klietz M, Schnur T, Drexel SC, Lange F, Paracka L, Huber MK, Dressler D, Höglinger
    GU, Wegner F. Alexithymia Is Associated with Reduced Quality of Life and Increased
    Caregiver Burden in Parkinson’s Disease. Brain Sci. 2020;10(6):401. Published 2020
    Jun 24.
  • Paracka L, Wegner F, Escher C, Klietz M, de Zwaan M, Abdalat M, Saryyeva A,
    Krauss JK. Body Concept and Quality of Life in Patients with Idiopathic
    Dystonia. Brain Sci. 2020;10(8):E488. Published 2020 Jul 28. Doi:
    10.3390/brainsci10080488
  • Fu T, Klietz M, Nösel P, Wegner F, Schrader C, Höglinger GU, Dadak M, Mahmoudi
    N, Lanfermann H, Ding X. Brain Morphological Alterations Are Detected in Early‐
    Stage Parkinson’s Disease with MRI Morphometry. Journal of Neuroimaging. 2020
    Aug 17;2020:231–7.

 

Abstracts

  • Klietz M, Depboylu C, Höglinger GU, Kobayashi K, Weihe E, M. Schäfer MK. (2011).
    Phenotypic Traits of Striatal Neurons Expressing Tyrosine Hydroxylase and Effects of
    Nigrostriatal Dopamine Pathway Injury. 7th IBRO Meeting Florence, Italy.
  • Klietz M, Depboylu C, Höglinger, Kobayashi K, Weihe E, M. Schäfer MK. (2011).
    Tyrosine hydroxylase-positive interneurons in mouse striatum express both VMAT2
    and VIAAT and exhibit plasticity for dynorphin. SFN Neuroscience Abstract,
    Washington, D.C., US.
  • Klietz M, Keber U, Carlsson T, Chiu W, Schäfer MK, Depboylu C (2012). Striatal
    Tyrosine Hydroxylase Positive Neurons are Regulated in a Mouse Model of L-DOPA
    Induced Dyskinesia 8th FENS Forum of Neuroscience, July 14th-18th, Barcelona, Spain.
  • Klietz M, Depboylu C, Chiu W, Kobayashi K, Weihe E, M. Schäfer MK. (2013).
    Expression analysis of dopaminergic marker genes in tyrosine hydroxylase positive
    neurons in the striatum of TH-eGFP mice by laser microdissection. Abs. T11-12C,
    Göttingen Meeting of the German Neuroscience Society 2013, Göttingen, Germany.
  • Keber U, Klietz M, Oertel WH, Höglinger GU, Carlsson T, Depboylu C (2014). Striatal
    tyrosine hydroxylase-positive neurons trigger L-DOPA-induced dyskinesia in mice.
    Neurowoche München, Germany.
  • M. Klietz, U. Keber, T. Carlsson, G. U. Höglinger, M.K-H Schäfer, E. Weihe and C.
    Depboylu (2016). L-DOPA-induced dyskinesia is associated with a deficient numerical
    downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons DGN
    Congress Mannheim, Germany.
  • Klietz M, Tulke A, Müschen LH, Schrader C, Dressler DW, Wegner F (2017).
    Versorgungssituation und Lebensqualität schwer betroffener Parkinsonpatienten unter
    palliativmedizinischen Aspekten. Deutscher Parkinsonkongress Baden-Baden,
    Germany.
  • Klietz, M.; Tulke, A.; Schrader C.; Diekstall, L.; Müschen, L.; Dressler, D.; Wegner,
    F. (2017) Quality of life and influencing factors in a local population of advanced
    geriatric Parkinson´s Disease patients. Movement Disorder Society 2017 Vancouver.
  • M. Klietz, A. Tulke, L. Diekstall, L. Müschen, C. Schrader, D. Dressler, F. Wegner
    (2017). Palliative care and quality of life in a German cohort of geriatric patients with
    advanced Parkinson´s disease. DGN Congress Leipzig, Germany.
  • Diekstall, L.; Klietz, M.; Tulke, A.; Lange, F; Schrader C.; Dressler, D.; Wegner, F.
    (2017). Caregiver burden of relatives from advanced Parkinson´s disease patients.
    DGN Congress Leipzig, Germany.
  • M. Klietz, P. Bronzlik, B. Schmitz, F. Wegner, D. Dressler, M. Dadak, XQ Ding
    (2018). Whole brain spectroscopy in early Parkinson’s disease: an exploratory MRI
    study. DGN Congress Berlin, Germany.
  • Drexel S, Klietz M, Kollewe K, Paracka L, Kutschenko A, Schulte-Sutum A, Kopp
    B, Lange F, Wegner F, Dressler D (2019) Dystonia treated with Botulinum Toxin:
    Quality of Life and Caregiver Burden. Toxins, Copenhagen, Denmark.